DE69203443D1 - Verwendung von interleukin-10 in der adoptive immunotherapie von krebs. - Google Patents

Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.

Info

Publication number
DE69203443D1
DE69203443D1 DE69203443T DE69203443T DE69203443D1 DE 69203443 D1 DE69203443 D1 DE 69203443D1 DE 69203443 T DE69203443 T DE 69203443T DE 69203443 T DE69203443 T DE 69203443T DE 69203443 D1 DE69203443 D1 DE 69203443D1
Authority
DE
Germany
Prior art keywords
interleukin
tils
cancer
adoptive immunotherapy
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69203443T
Other languages
English (en)
Other versions
DE69203443T2 (de
Inventor
Di-Hwei Hsu
Kevin Moore
Hergen Spits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69203443D1 publication Critical patent/DE69203443D1/de
Publication of DE69203443T2 publication Critical patent/DE69203443T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69203443T 1991-01-16 1992-01-15 Verwendung von interleukin-10 in der adoptive immunotherapie von krebs. Expired - Fee Related DE69203443T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64134291A 1991-01-16 1991-01-16
PCT/US1992/000067 WO1992012726A1 (en) 1991-01-16 1992-01-15 Use of interleukin-10 in adoptive immunotherapy of cancer

Publications (2)

Publication Number Publication Date
DE69203443D1 true DE69203443D1 (de) 1995-08-17
DE69203443T2 DE69203443T2 (de) 1995-12-07

Family

ID=24571960

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69203443T Expired - Fee Related DE69203443T2 (de) 1991-01-16 1992-01-15 Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.

Country Status (17)

Country Link
US (1) US5776451A (de)
EP (2) EP0495639A1 (de)
JP (1) JPH06505250A (de)
CN (1) CN1063308A (de)
AT (1) ATE124866T1 (de)
AU (1) AU1273992A (de)
DE (1) DE69203443T2 (de)
DK (1) DK0567586T3 (de)
ES (1) ES2074879T3 (de)
GR (1) GR3017597T3 (de)
IE (1) IE68836B1 (de)
IL (1) IL100667A0 (de)
MX (1) MX9200161A (de)
MY (1) MY108267A (de)
NZ (1) NZ241321A (de)
WO (1) WO1992012726A1 (de)
ZA (1) ZA92304B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
AU707019B2 (en) * 1994-01-20 1999-07-01 Schering Corporation Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
AU2062497A (en) * 1996-02-28 1997-09-16 University Of Medicine And Dentistry Of New Jersey Antisense interleukin 10 and methods of use
DE69637856D1 (en) 1996-08-30 2009-04-16 Human Genome Sciences Inc Interleukin-19.
AU6517900A (en) * 1999-08-03 2001-02-19 Smith & Nephew, Inc. Controlled release implantable devices
DE60138222D1 (de) 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
EP2295450B1 (de) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegyliertes interleukin 10
WO2004073624A2 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
US7294262B2 (en) * 2003-08-27 2007-11-13 Sta-Rite Industries, Llc Modular fluid treatment apparatus
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
US20110268757A1 (en) 2008-12-03 2011-11-03 Institut Pasteur Use of phenol-soluble modulins for vaccine development
PT2379115T (pt) 2008-12-17 2018-01-03 Merck Sharp & Dohme Produção de mono- e di-peg-il-10; e utilizações
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza
US8956607B2 (en) 2009-11-30 2015-02-17 Biotest Ag Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE)
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (de) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
WO2014172392A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
WO2015063613A2 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
RU2016122957A (ru) 2013-11-11 2017-12-19 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
EP3110429A4 (de) 2014-02-27 2018-02-21 Lycera Corporation Adoptive zelltherapie unter verwendung eines agonisten des retinsäurenrezeptor-assoziierten orphanrezeptors gamma und dazugehörige therapeutische verfahren
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US10350270B2 (en) 2014-10-14 2019-07-16 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CA2963995A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2019143883A2 (en) * 2018-01-18 2019-07-25 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
CN110669139A (zh) * 2019-09-18 2020-01-10 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CN114805538B (zh) * 2022-05-20 2023-06-09 广州智瓴生物医药有限公司 一种增强til功效的培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1990004633A1 (en) * 1988-10-21 1990-05-03 Brigham And Women's Hospital ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR
WO1990010059A1 (en) * 1989-02-21 1990-09-07 Terumo Corporation A process for the generation of proliferating cd4 lymphocytes
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same

Also Published As

Publication number Publication date
EP0567586A1 (de) 1993-11-03
ZA92304B (en) 1992-09-30
MY108267A (en) 1996-09-30
DE69203443T2 (de) 1995-12-07
CN1063308A (zh) 1992-08-05
AU1273992A (en) 1992-08-27
MX9200161A (es) 1992-07-01
DK0567586T3 (da) 1995-12-04
IE68836B1 (en) 1996-07-10
US5776451A (en) 1998-07-07
GR3017597T3 (en) 1996-01-31
ATE124866T1 (de) 1995-07-15
JPH06505250A (ja) 1994-06-16
IL100667A0 (en) 1992-09-06
IE920113A1 (en) 1992-07-29
EP0567586B1 (de) 1995-07-12
WO1992012726A1 (en) 1992-08-06
EP0495639A1 (de) 1992-07-22
ES2074879T3 (es) 1995-09-16
NZ241321A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
ATE124866T1 (de) Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
Niederwieser et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses.
Rook et al. The immunopathogenesis of cutaneous T-cell lymphoma: abnormal cytokine production by Sézary T cells
ATE20073T1 (de) Homogenes human-interleukin-2 und verfahren zu seiner herstellung.
EP0668781A4 (de) Lymphokine gentherapie bei krebs.
ATE163675T1 (de) Zytotoxischer lymphozyten-reifefaktor
EP0211769A3 (en) Adoptive immunotherapy as a treatment modality in humans
ZA967756B (en) Adoptive immunitherapy using macrophages sensitized with heat shock protein-epitope complexes
DK226288A (da) Fremgangsmaade til fremstilling af lak-celler in vitro
AU6733487A (en) Mammalian interleukin-4
Talmadge et al. Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes
ATE167519T1 (de) T-zellen-wachstumsfaktor
Flynn et al. Production of interleukin-1 and interleukin-2 in allogeneic mixed lymphocyte cultures under copper, magnesium and zinc deficient conditions
EP0094317A3 (de) Herstellung von Interleukin und dessen analogen immunregulierenden Faktoren
DE3683956D1 (de) In einem serumfreien medium in suspension kultivierte humane monozyten.
SE8106944L (sv) Virusinhiberande substans och forfarande for framstellning derav
YU4792A (sh) Postupak gajenja tumornih infiltirajućih limfocita
Hansson Growth and differentiation factors for B and T cells
JPS57115180A (en) Preparation of human tyroid-stimulating hormone
GR3018004T3 (en) Process to prepare metastasis-inhibitory factor.
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
GB8729410D0 (en) Method for production of lymphokine activated killer(lak)cells & lak cells so produced

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee